Significant Accounting Policies - Additional Information (Details) - USD ($)						3 Months Ended			9 Months Ended		12 Months Ended
	Aug. 19, 2022	Jan. 14, 2022	Oct. 12, 2021	Mar. 19, 2021	Jan. 25, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Oct. 04, 2021
Schedule Of Significant Accounting Policies [Line Items]
Upfront nonrefundable payment					$ 1,000,000.0
Loan in principal amount					$ 4,000,000.0
Issuance and bore interest rate					6.00%
Reimbursement payment				$ 14,000,000.0
Collaboration agreement amount				25,000,000.0
Development payments				10,000,000.0
Deferred collaboration funding						$ 10,600,000			$ 10,600,000
Deferred collaboration funding, current						10,598,201			10,598,201		$ 15,825,938
Cash in excess of FDIC insured limit						6,100,000			6,100,000		12,500,000
Preclinical or clinical study expense included in accounts payable and accrued expenses.						1,000,000.0			1,000,000.0		200,000
Income tax expense (benefit)						0	$ 0		0	$ 0
Uncertain tax positions, accruals						0	0		0	0
Accruals for interest or penalties related to income tax matters						$ 0	$ 0		$ 0	$ 0
ASU No. 2020-06
Schedule Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted						true			true
Change in accounting principle, accounting standards update, adoption date						Mar. 31, 2021			Mar. 31, 2021
ASU No. 2021-10
Schedule Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted						true			true
Change in accounting principle, accounting standards update, adoption date						Dec. 31, 2021			Dec. 31, 2021
Change in accounting principle, accounting standards update, immaterial effect						true			true
ASU No. 2021-04
Schedule Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted						true			true
Change in accounting principle, accounting standards update, adoption date						Mar. 31, 2022			Mar. 31, 2022
Change in accounting principle, accounting standards update, immaterial effect						true			true
Maximum
Schedule Of Significant Accounting Policies [Line Items]
Cash, FDIC insured amount						$ 250,000			$ 250,000
Bridge Loan
Schedule Of Significant Accounting Policies [Line Items]
Minimum cash balance required by the loan covenants	$ 1,500,000
Bridge Loan | 20 Days Following Liquidity Trigger Date
Schedule Of Significant Accounting Policies [Line Items]
Minimum cash balance required by the loan covenants	4,000,000.0
Bridge Loan | 40 Days Following Liquidity Trigger Date
Schedule Of Significant Accounting Policies [Line Items]
Minimum cash balance required by the loan covenants	$ 6,500,000
Bridge Loan | Minimum | 20 Days Following Liquidity Trigger Date
Schedule Of Significant Accounting Policies [Line Items]
Number of days required for cash balance	20 days
Bridge Loan | Minimum | 40 Days Following Liquidity Trigger Date
Schedule Of Significant Accounting Policies [Line Items]
Number of days required for cash balance	40 days
Relief
Schedule Of Significant Accounting Policies [Line Items]
Non-cash reduction recognized in secured loan									4,000,000.0
Collaboration Agreement | Second Development Payment
Schedule Of Significant Accounting Policies [Line Items]
Deferred collaboration funding						10,600,000			10,600,000
Deferred collaboration funding, current						10,600,000			10,600,000
Deferred collaboration funding, cash received						$ 35,000,000.0			35,000,000.0
Revenue recognized											$ 1,300,000
Offset to research and development expenses									12,900,000
Offset to general and administrative expenses									$ 10,300,000
Collaboration Agreement | Relief
Schedule Of Significant Accounting Policies [Line Items]
Cash payment received				10,000,000.0				$ 10,000,000.0
Reimbursement payment				14,000,000.0	$ 14,000,000.0
Repayment of outstanding balance of prior loan and interest				4,000,000.0	$ 4,000,000.0
Development and commercial launch costs				$ 20,000,000.0
Net profit split ratio based on territory				60.00%	60.00%
Percentage of royalty net sales received				15.00%	15.00%
Milestone payment to be received				$ 6,000,000.0	$ 6,000,000.0
Potential proceeds from development payments subject to new drug application												$ 10,000,000.0
Proceeds from first tranche of development payments subject to new drug application			$ 5,000,000.0
Percentage of development and commercialization services				60.00%
Percentage of payment net profit territory				60.00%
Upfront non-refundable payment received					1,000,000.0
Collaboration Agreement | Relief | Maximum
Schedule Of Significant Accounting Policies [Line Items]
Development and commercial launch costs					20,000,000.0
Development payments				$ 20,000,000.0
Collaboration Agreement | Relief | Second Development Payment
Schedule Of Significant Accounting Policies [Line Items]
Potential proceeds from development payments subject to new drug application												$ 10,000,000.0
Proceeds from first tranche of development payments subject to new drug application			5,000,000.0
Waiver and Agreement | Relief | Second Development Payment
Schedule Of Significant Accounting Policies [Line Items]
Proceeds from first tranche of development payments subject to new drug application		$ 5,000,000.0	$ 5,000,000.0
Proposed Collaboration and License Agreement
Schedule Of Significant Accounting Policies [Line Items]
Upfront non-refundable payment received				$ 1,000,000.0
Proposed Collaboration and License Agreement | Relief
Schedule Of Significant Accounting Policies [Line Items]
Upfront non-refundable payment received					$ 1,000,000.0